There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT) and Cytokinetics (CYTK) with bullish sentiments.
Sarepta Therapeutics (SRPT)
In a report released today, Danielle Brill from Raymond James maintained a Buy rating on Sarepta Therapeutics. The company’s shares closed last Monday at $151.05.
According to TipRanks.com, Brill is a 5-star analyst with an average return of 23.9% and a 63.4% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and PTC Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $188.18 average price target, representing a 21.4% upside. In a report issued on December 1, Mizuho Securities also reiterated a Buy rating on the stock with a $192.00 price target.
See today’s analyst top recommended stocks >>
Cytokinetics (CYTK)
In a report released today, Dane Leone from Raymond James maintained a Buy rating on Cytokinetics. The company’s shares closed last Monday at $16.31.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 16.9% and a 64.5% success rate. Leone covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $29.13 average price target, implying a 70.1% upside from current levels. In a report issued on November 23, Mizuho Securities also assigned a Buy rating to the stock with a $31.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
